Search

Aurinia Pharmaceuticals Inc

Cerrado

SectorSanidad

16.01 -0.37

Resumen

Variación precio

24h

Actual

Mínimo

16.01

Máximo

16.16

Métricas clave

By Trading Economics

Ingresos

3.1M

37M

Ventas

5.5M

83M

P/B

Media del Sector

7.053

56.597

BPA

0.28

Margen de beneficios

44.958

Empleados

128

EBITDA

4.8M

55M

Dividendos

By Acuity

Próximas Ganancias

3 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

266M

2.1B

Apertura anterior

16.38

Cierre anterior

16.01

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

136 / 339 Clasificación en Healthcare

Aurinia Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 sept 2026, 20:06 UTC

Aurinia Pharmaceuticals shares are lower today, influenced by broader market declines amid macroeconomic factors, including the European Central Bank's interest rate hike.

9 sept 2026, 20:41 UTC

Aurinia Pharmaceuticals Inc shares are higher in after-market trading, showing increased investor interest despite no specific company news, remaining above their 20-day moving average.

8 sept 2026, 23:36 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

1 sept 2026, 20:08 UTC

Aurinia Pharmaceuticals is declining amid broader market losses and rising inflation concerns, with no specific company news identified to explain the movement.

26 ago 2026, 20:08 UTC

News

Aurinia Pharmaceuticals shares are lower amid broader Biotechnology sector weakness. A Form 4 filing revealed a $355,000 insider share sale by Chief Legal Officer Stephen P. Robertson.

25 ago 2026, 19:36 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment, despite pulling back from earlier session highs. No specific news was identified.

24 ago 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of declines observed over the past three sessions. No specific news was identified.

21 ago 2026, 23:06 UTC

Aurinia Pharmaceuticals Inc. shares are higher in after-market hours, reflecting routine trading activity and maintaining a position above the 20-day moving average.

20 ago 2026, 21:46 UTC

Aurinia Pharmaceuticals Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

19 ago 2026, 23:02 UTC

News

Aurinia Pharmaceuticals settled patent litigation with Teva, securing exclusivity for voclosporin until December 2036. Shares rose in after-hours trading following the announcement.

18 ago 2026, 19:56 UTC

Aurinia Pharmaceuticals Inc is trading higher today, though no specific news has been identified. Rising Treasury yields may pose challenges for equities.

17 ago 2026, 20:02 UTC

Social Media

Aurinia Pharmaceuticals shares are lower amid broader market declines and rising crude oil prices, despite some social media chatter about potential buyout interest.

14 ago 2026, 19:26 UTC

Aurinia Pharmaceuticals shares are higher today, rebounding after earlier volatility amid broader market concerns over disappointing U.S. retail sales figures.

13 ago 2026, 19:56 UTC

News

Aurinia Pharmaceuticals shares are lower today, despite ongoing sales growth of Lupkynis and a recent acquisition of Kezar Life Sciences.

11 ago 2026, 20:06 UTC

Aurinia Pharmaceuticals Inc shares are trading lower today, continuing a trend of three consecutive daily declines amid no specific news to explain the movement.

10 ago 2026, 20:06 UTC

News

Aurinia Pharmaceuticals shares decline following multiple downgrades from research firms, despite Royal Bank of Canada raising its price target to $16.00.

7 ago 2026, 19:16 UTC

News

Aurinia Pharmaceuticals shares are lower today, despite earlier gains. RBC Capital raised the price target to $16.00 from $15.00, maintaining a Sector Perform rating.

6 ago 2026, 20:02 UTC

Event
News

Aurinia Pharmaceuticals reported second-quarter EPS of $0.28, exceeding estimates. The stock is higher today amid strong financial results and reaffirmed revenue guidance for 2026.

4 ago 2026, 19:46 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment and a decline in crude oil prices, which may benefit consumer spending.

3 ago 2026, 22:01 UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

1 ago 2026, 00:01 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

31 jul 2026, 21:01 UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

30 jul 2026, 20:31 UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

29 jul 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

28 jul 2026, 19:36 UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

27 jul 2026, 19:16 UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

24 jul 2026, 18:26 UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

22 jul 2026, 19:46 UTC

Aurinia Pharmaceuticals shares are lower today, continuing a decline since Tuesday's close. The stock is near its one-month trading range's lower end.

21 jul 2026, 19:16 UTC

Aurinia Pharmaceuticals is higher today, supported by a broader market uptick as investor interest in AI-related stocks grows ahead of major tech earnings.

20 jul 2026, 20:01 UTC

Aurinia Pharmaceuticals is lower today, reflecting broader market declines amid geopolitical tensions and oil price fluctuations. The stock hit a session low earlier.

Comparación entre iguales

Cambio de precio

Aurinia Pharmaceuticals Inc previsión

Consenso

By TipRanks

Compra Moderada

3 ratings

2

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

136 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
help-icon Live chat